嗅觉测试和灰质体积:一种联合方法来预测转化为阿尔茨海默氏症.
Claudia Casadio1, Daniela Ballotta1, Francesco Ricci1
1Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Brain sciences
|March 28, 2025
概括
轻度认知障碍 (MCI) 的嗅觉衰退和脑缩可以预测阿尔茨海默病 (AD) 的进展. 在MCI患者中,早期的嗅觉和形态评估可能能够及时进行干预.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 老年学是一门学科.
背景情况:
- 嗅觉衰退是一种常见的衰老症状,在像阿尔茨海默氏症 (AD) 这样的神经退行性疾病中很普遍.
- 嗅觉缺陷被认为是轻度认知障碍 (MCI) 进展到AD的潜在早期标志物.
- 嗅觉功能障碍,大脑缩和MCI转化为AD之间的联系需要进一步调查.
研究的目的:
- 研究MCI患者的嗅觉相关的形态和行为变化.
- 确定这些变化是否可以预测MCI进展到AD.
- 探索MCI中嗅觉缺陷和大脑缩之间的关系.
主要方法:
- 研究包括27名MCI患者 (13名转换为AD - cMCI,14名稳定 - sMCI) 和35名健康对照 (HC).
- 嗅觉功能使用Burgarth Sniffin' Sticks测试 (门,歧视,识别) 进行评估.
- 用Voxel-Based Morphometry (VBM) 分析大脑结构,以确定大脑缩的模式.
主要成果:
- 嗅觉区分和识别测试区分HC从MCI和cMCI从sMCI.
- 嗅觉性能与稳定的MCI中的内存以及转换器中的执行功能相关.
- 在AD转换之前的cMCI患者的嗅觉皮层中,VBM揭示了明显的缩模式,与认知功能相关.
结论:
- 定量嗅觉和形态模式作为MCI进展到AD的非侵入性生物标志物.
- 在MCI发病时评估这些模式可以更早地检测和干预.
- 这些发现支持使用嗅觉和脑成像来预测MCI患者的AD发展.
相关概念视频
Olfaction
40.5K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
40.5K
Olfactory Receptors: Location and Structure
10.6K
The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
10.6K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42


